This is a working overview of obesity research, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-14 and is reviewed periodically as new material appears.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
=== 4 April === The United States government announced a $2.6 billion (USD) aid package to Ukraine which includes ammunition for HIMARS, air defense interceptors, artillery rounds, small arms ammunition, and anti-drone systems.
== See also == Blood irradiation therapy – Alternative medical procedure Light therapy – Therapy involving intentional exposure to sunlight Neurotechnology Neurotherapy Photomedicine – Study of light's effect on human health Photorejuvenation – Skin treatment
=== Breast cancer === Hormone antagonists are used widely in anticancer treatments, such as the drug tamoxifen, an anti-estrogen that binds to estrogen receptors to slow the growth of some estrogen receptor-positive breast cancers. Aromatase inhibitors (AIs) are also prescribed as a breast cancer treatment, especially after mastectomies. AIs work by blocking the action of the aromatase enzyme, which converts androgens, like testosterone, into estrogen. Aromatase inhibitors can be used in conjunction with estrogen receptor inhibitors to treat estrogen receptor-positive breast cancers in women who have gone through menopause already.
=== Cardiovascular === Cardiomyopathy/heart failure - Angiotensin receptor blockers (ARBs), angiotensin converting enzyme inhibitors (ACEis), angiotensin receptor-neprilysin inhibitors (ARNis), beta-blockers, calcium channel blockers, loop diuretics, thiazide diuretics, mineralocorticoid receptor antagonists (MRAs), vasodilators Note that blood pressure control is also renally protective.
=== Indirect separation of enantiomer === Indirect enantiomer separation involves the interaction between the chiral analyte (CA) of interest and the suitable reactive CS (in this case it is an enantiopure chiral derivatizing agent, CDA) leading to the formation of a covalent diastereomeric complex that can be separated with an achiral chromatographic technique. Therapeutic agents often contain reactive functional groups (amino, hydroxyl, epoxy, carbonyl and carboxylic acid, etc.) in their structures. They are converted into covalently bonded diastereomeric derivatives using enantiomerically pure chiral derivatizing agent. The diastereomers thus formed unlike enantiomers, exhibit different physicochemical properties in an achiral environment and are eventually separated as a result of differential retention time on a stationary phase. The success of this approach depends on the availability of stable enantiopure chiral derivatizing agent (CDA) and on the presence of a suitable reactive functional group in the chiral drug molecule for covalent formation of diastereomeric derivative. The reaction of a racemic, (R,S)- Drug with a chirally and chemically pure chiral derivatizing agent, (R')-CDA, will afford diastereomeric products, (R)-Drug-(R')-CDA + (S)-Drug-(R')- CDA. The chiral derivatization reaction scheme is illustrated in the box on the right hand side. In contrast to enantiomers, diastereomers have different physicochemical properties that make them separable on regular achiral stationary phases.
Sources: en.wikipedia.org
==== Mining and extraction of fuels ==== According to the World Nuclear Association, coal from all deposits contains traces of various radioactive substances, particularly radon, uranium and thorium. These substances are released during coal mining, especially from surface mines, through power plant emissions, or power plant ash, and contribute to terrestrial radiation exposure through their exposure pathways. In December 2009, it was revealed that oil and gas production generates millions of tons of radioactive waste each year, much of which is improperly disposed of without detection, including 226Radium and 210Polonium. The specific activity of the waste ranges from 0.1 to 15,000 becquerels per gram. In Germany, according to the Radiation Protection Ordinance of 2001, the material is subject to monitoring at one Becquerel per gram and would have to be disposed of separately. The implementation of this regulation has been left to the industry, which has disposed of the waste carelessly and improperly for decades.
== Associated conditions == Diseases of the pituitary, the gland that produces, among others, the hormone ACTH Hypopituitarism, the hyposecretion of ACTH in the pituitary, leading to secondary adrenal insufficiency (a form of hypocorticism) Addison's disease, the primary adrenal insufficiency (another form of hypocorticism) Cushing's syndrome, hypercorticism, one of the causes is hypersecretion of ACTH Small cell carcinoma, a common cause of ACTH secreted ectopically Congenital adrenal hyperplasia, diseases in the production of cortisol Nelson's syndrome, the rapid enlargement of the ACTH producing pituitary after the removal of both adrenal glands Adrenoleukodystrophy, can be accompanied by adrenal insufficiency West syndrome ("infantile spasms"), a disease where ACTH is used as a therapy Postorgasmic illness syndrome (POIS), through production of tyrosine hydroxylase and dopamine β-hydroxylase, which two enzymes comprise the biochemical mechanism by which norepinephrine and epinephrine are produced. Critical illness-related corticosteroid insufficiency DAVID syndrome, a genetic disorder that is characterized by adrenocorticotropic hormone deficiency combined with common variable immunodeficiency and hypogammaglobulinemia.
=== Mechanism of action === Codeine is an opiate and an agonist of the μ-opioid receptor (MOR). It acts on the central nervous system to have an analgesic effect. It is metabolised in the liver to produce morphine which is ten times more potent against the MOR. Opioid receptors are G protein-coupled receptors that positively and negatively regulate synaptic transmission through downstream signalling. Binding of codeine or morphine to the μ-opioid receptor results in hyperpolarization of the neuron leading to the inhibition of the release of nociceptive neurotransmitters, causing an analgesic effect and increased pain tolerance due to reduced neuronal excitability.
Stimulated by a severe epidemic, variolation was first employed in North America in 1721. The procedure had been known in Boston since 1706, when preacher Cotton Mather learned it from Onesimus, a man he held as a slave, who – like many of his peers – had been inoculated in Africa before they were kidnapped. This practice was widely criticized at first. However, a limited trial showed six deaths that had occurred out of 244 were variolated (2.5%), while 844 out of 5980 died of natural disease (14%), and the process was widely adopted throughout the colonies. The inoculation technique was documented as having a mortality rate of only one in a thousand. Two years after Kennedy's description appeared, March 1718, Dr. Charles Maitland successfully inoculated the five-year-old son of the British ambassador to the Turkish court under orders from the ambassador's wife Lady Mary Wortley Montagu, who four years later introduced the practice to England. An account from letter by Lady Mary Wortley Montagu to Sarah Chiswell, dated 1 April 1717, from the Turkish Embassy describes this treatment:
In 1973 "by Direction of the President, Major General Liu Wan-Tsai, Chinese Air Force, [was] awarded the Legion of Merit (Degree of Officer) for exceptionally meritorious service as Air Attache, Embassy of the Republic of China, Washington, D.C., from 4 April 1969 to 27 July 1972." In 1996, Lieutenant General Roméo Dallaire of the Canadian Army was made an Officer of the Legion for his role as Commander of the United Nations peacekeeping force in Rwanda during the civil war and subsequent genocide. On 18 December 1980 Major General Shlomo Inbar, Israel Army, was made an Officer of the Legion of Merit for his exceptionally meritorious conduct in the outstanding performance of duties as Defense and Armed Forces Attache, Embassy of Israel to the United States of America, from July 1977 to August 1980. In 2000, Lieutenant General Danfer G. Suarez was made an Officer of the Legion "Exceptionally meritorious conduct in the performance of outstanding services as the Peruvian Air Attache from 1997 to 1998. In 2006, Lieutenant General Nick Houghton, British Army, "in recognition of gallant and distinguished services during coalition operations in Iraq." In 2007, Lieutenant General Sir Robert Fry, Royal Marines, "in recognition of gallant and distinguished service during coalition operations in Iraq. Lieutenant General Tariq Khan became the fourth Pakistani officer to receive the award for meritorious services as a liaison officer at CENTCOM during Operations Enduring Freedom (December 9, 2007).
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.